Rainbow Seed Fund Backs Pireta
A Smart Textiles Technology Developed at the National Physical Laboratory Rainbow Seed Fund, an early-stage…read more
The Rainbow Seed Fund is a £24m, early-stage venture capital fund dedicated to kick-starting promising technology companies developed at some of the UK’s largest publicly-funded research facilities. These companies are linked to the rapidly expanding science and technology campuses and the field of synthetic biology.
Created in 2002, the Rainbow Seed Fund is backed by ten UK publicly-funded research organisations and the Department of Business, Innovation and Skills (BIS). The Fund holds investments in some of the UK’s most innovative companies in areas as diverse as novel antibiotics, research into Alzheimer’s disease, “green” chemicals and airport security.
We’re prepared to invest early and help build a commercial proposition around a technology to attract additional investment needed to get to market.
1. Projects and companies arising from the world-class research carried out in our Partner laboratories across the UK, including those at Rutherford Appleton Laboratory (STFC), Porton Down (Dstl) and Babraham Institute (BBSRC). View full list of partners.
2. Companies based at our partners’ national science and innovation campuses in Oxford, Cambridge, Warrington and Norwich. Read more about partner campuses.
3. Companies working in the field of synthetic biology: Synthetic biology is an exciting new discipline based on the design and engineering of biologically-based parts, novel devices and systems and the redesign of existing, natural biological systems.
Over the past decade, the Rainbow Seed Fund has:
Fund Amount 24m
2 Profitable Exits
Spinout developing novel hand-held reader to help in the fight against antibiotic resistance Rainbow Seed…read more
Nemesis Bioscience today announced the successful completion of its latest funding round, bringing total seed…read more
May 03, 2017 Justin Petrone www.genomeweb.com British molecular diagnostics company Cytox plans to make…read more
Collaboration to generate tumor targeting drug conjugates and immuno-oncology therapeutics Crescendo Biologics Limited (Crescendo), the…read more
Synthace Ltd., a London based technology company developing Antha, a high level language and operating…read more
Cambridge, UK: 2 February 2016 – Crescendo Biologics Limited (Crescendo), the drug discovery and developer…read more
Antibody veteran joins new CEO as Crescendo redirects strategy to Oncology focus Cambridge, UK: 17…read more
Crescendo Biologics Limited, the drug discovery and developer of Humabody™ VH therapeutics, has announced the…read more
Synthace and Dow AgroSciences LLC, a wholly owned subsidiary of The Dow Chemical Company (NYSE:DOW), today…read more
Desktop Genetics Ltd (“DTG” or “the Com pany”), a UK bioinformatics company aiming to…read more
Quethera, a gene therapy company developing a treatment for glaucoma that could prevent blindness, has…read more
20 July 2015: Oxford, UK. Cytox Ltd, an innovative developer of assays for risk assessment…read more
Combining excellence in industrial biotechnology May 18th, 2015 – Welwyn Garden City, UK and Baltimore,…read more
18 July 2014 - Spectral Edge announces today the completion of a £300K financing round…read more
VH domains are the smallest, most robust antibody fragments and as such have advantages for…read more
KEIT Ltd is a brand new, forward thinking spin out company from the Science and…read more
Suitable for low temperatures and high vibrations, immune to EMI Reduces system weight and complexity…read more
Tue, 17/01/2012 - 12:26 Cobalt Light Systems has received European approval for its revolutionary INSIGHT100…read more
Just one drop of liquid can destroy your phone or tablet! Acting like a barrier,…read more